sales@towardshealthcare.com
+1 804-441-9344
February 2026
The global metabolomics market was evaluated at US$ 3.64 billion in 2025 and is expected to reach around US$ 12.84 billion by 2035, growing at a CAGR of 13.43% from 2024 to 2034.
The metabolomics market has grown rapidly as a result of metabolomics, which combines techniques to identify and analyze cellular metabolites using advanced analytical methods with statistical and multivariate methods for data extraction and interpretation. Significant investments have been made in the development of analytical methods for different cellular products such as gene expression (transcripts), proteins, and metabolites. This method has been applied to many different biological systems using GC-MS, including plant, microbial, urine, and plasma. Metabolomics uses additional studies such as LC-MS/MS, GC-MS, and/or NMR to identify and characterize as many metabolites as possible. It can also be used for metabolic fingerprints (or footprints of exogenous and/or secreted metabolites).
Metabolomics is increasingly recognized as an important enabler in biotechnological advances, bridging the gap between genotype and phenotype to provide a deeper understanding of cellular function. Its applications cover a wide range of areas, including phenotyping genetically modified plants, testing genetic diversity, determining gene function, and monitoring responses to biotic and abiotic stresses. Metabolomics not only helps discover new biological insights by identifying significant changes in metabolites but also supports the development of new biotechnological solutions. Analysis and data mining of metabolomics datasets can generate new perspectives for biotechnology and discover new targets, thereby accelerating the growth of the metabolomics market. This industry expansion highlights the importance of metabolomics in fields such as agriculture, health research, and the biotechnology industry, making it an important tool for future scientific and technological advancement.
The biggest limitation to the growth of the metabolomics market is the difficulty associated with identifying biomarkers needed to understand changes in the body. This step is also important in metabolomics studies, as metabolite identification (especially from LC-MS data) is more difficult as libraries are not re-developed compared to GC-MS analysis. Furthermore, inconsistencies in analytical platforms, column types, gradients, and collision energies used in tandem mass spectrometry in the laboratory further complicate data comparison and reproducibility. These economic barriers hinder the general application and activation of metabolomics, making it difficult for the industry to grow and fully realize its potential across the market.
In recent years, the use of metabolomics in nutrition research has increased, leading to advances in personalized nutrition and public health research. These studies investigate the link between diet and health or disease, and the diet is related to the use of whole foods, specific foods, or products such as micronutrients or phytochemicals. However, measuring the impact of these interventions can be challenging because metabolic changes are so subtle and often difficult to detect. Metabolomics plays an important role in overcoming these challenges, identifying target biomarkers of dietary intake, developing personalized nutrition strategies, and supporting large-scale research studies to better understand the relationship between nutrition and health. Therefore, developing metabolomics applications in these areas will not only improve understanding of the role of nutrition in health but also create a significant time for the growth of the metabolomics market, positioning it as a leader in the field of nutrition, a key enabler of health innovation.
North America is expected to lead the market during the forecast period as the number of chronic diseases in the United States is steadily increasing by 7 to 8 million people every 5 years. Chronic diseases affect 50% of the population, and their care accounts for more than 85% of medical expenses. This has become an epidemic. Increase access to quality healthcare. Nearly 50% of US consumers now consider health the most important thing in their daily lives, an increase from 42%. Healthcare in the United States, unlike any other industry, is a complex stakeholder system comprised of patients, payers, and providers. The country’s more than 6,600 biotech companies are committed to innovation to solve complex medical problems and save more lives. Investments in the medical field are vital, driving the growth of the metabolomics market.
Asia Pacific is expected to grow significantly during the forecast period as healthcare providers in the region adopt more technologies, including AI and cloud technology, in their standards of care. Increasing healthcare spending in Asia Pacific is inevitable. The growth of the metabolomics market is driven by the increasing demand for medical devices in the Asia Pacific, which can be attributed to several factors, such as a rapidly aging population, the arrival of a growing middle class, health information, and key government initiatives, thus leading the growth of market.
Asia is expected to experience significant growth in the metabolomics market during the forecast period due to several factors. The increasing prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, is driving the demand for advanced diagnostic tools and personalized treatment approaches. Rapid advancements in healthcare infrastructure, particularly in countries like China and India, are further boosting research and development in metabolomics. The expansion of the pharmaceutical and biotechnology industries in the region is accelerating drug discovery and development. Additionally, the adoption of precision medicine, technological advancements in analytical techniques, and a growing focus on early disease detection are all contributing to the growth of the metabolomics market across Asia.
| Key Elements | Scope |
| Market Size in 2026 | USD 4.13 Billion |
| Projected Market Size in 2035 | USD 12.84 Billion |
| CAGR (2026 - 2035) | 13.43% |
| Leading Region | North America |
| Market Segmentation | By Product and Service, By Application, By Indication, By End-user, By Geography |
| Top Key Players | Thermo Fisher, Agilent, Metabolon, Shimadzu Corporation, Bruker, Waters Corporation, Biotree, LECO Corporation, Biocrates Life Sciences AG, Human Metabolome Technologies, Metware, Applied Protein Technology, Creative Proteomics, Diagnostic Solutions Laboratory |
By product & service, metabolomics instrument segments constitute the metabolomics market by 40% as they allow researchers to analyze non-volatile compounds without the need for derivatization to increase volatility, reduce the formation of fragment ions, and simplify the spectral description of complex compounds. While the bioinformatics tools and services segment is the fastest growing in the forecast period due to its ability to process raw spectral data, analytical analysis to identify major metabolites has potential nature linkages with metabolite data for metabolite identification and bioinformatics analysis.
Metabolomics combined with sophisticated bioinformatics analysis and with the application of mathematical modeling can generate a metabolic snapshot of patients. This is done to classify patients into subpopulations and subgroups based on disease and risk. This helps narrow down a list of individuals who require medical intervention and treatment.
By application, the biomarker discovery segment held the largest share of the market by 35% in 2025. The utilization of metabolic biomarkers to test pathophysiological health status for patients has increased in several years, this acts as a major growth factor for the segment to expand. Moreover, the integration of advanced technologies and advancements in metabolomics are seen to promote the segment’s growth.
| Segment | Share 2025 (%) |
| Cancer | 40% |
| Cardiovascular Disorders | 20% |
| Neurological Disorders | 10% |
| Metabolic Disorders | 15% |
| Others | 15% |
By indication, the cancer segment led the metabolomics market in 2025, with the rising demand for advanced testing methods or detection methods for cancer is observed to sustain the segment’s growth during the forecast period. Moreover, the rising number of cancer therapies and rising number of cancer patients are major factors to promote the growth of the segment. Additionally, the increase in funding for cancer and other associated diseases studies is observed to expand the segment’s growth in the upcoming period.
By end user, the academic and research institutes segment dominates the metabolomics market by 40%, as there is great potential for metabolomics to be used in public research to assess the effects of nutrients, drugs, and environmental impacts. The pharmaceutical and biotechnology companies segment is fastest growing, as mass spectrometry-based metabolomics plays an important role in clinical research, disease treatment, medicine, animal research and plants, agricultural research, and food. Research methods include sample preparation, sample analysis, data analysis, and metabolic process analysis.
By Product and Service
By Application
By Indication
By End-user
By Geography
February 2026
February 2026
February 2026
February 2026